IJMS, Vol. 26, Pages 9806: Transthyretin Amyloidosis—One of the Causes of Heart Failure in Patients with Severe Clinical Course of COVID-19

International Journal of Molecular Sciences doi: 10.3390/ijms26199806

Authors:
Zarina Gioeva
Liudmila Mikhaleva
Nikita Gutyrchik
Nikolay Shakhpazyan
Valentina Pechnikova
Konstantin Midiber
Andrej Kontorshchikov
Elizaveta Zentsova
Lev Kakturskij

Wild-type transthyretin amyloidosis is an underdiagnosed condition that significantly contributes to mortality in the elderly population. This histopathological study describes autopsy findings in patients with severe clinical course of COVID-19 and ATTR not identified during life. Autopsy findings in the myocardium were analyzed in 19 patients with pre-existing ATTR who died from severe COVID-19. RT PCR was used for pre- and post-mortem detection of SARS-CoV-2 RNA. Immunohistochemical typing was performed with a broad panel of antibodies against different amyloid types. Autopsy specimens from the myocardium and lungs were positive for SARS-CoV-2 RNA in 10 (53%) cases. Microscopic examination of the myocardium revealed focal cardiosclerosis and cardiomyocyte dissociation in 15 (68%) cases, hypertrophy and atrophy of cardiomyocytes in 17 (77%) and 7 (32%), respectively, and myocarditis in 4 (18%) cases. Immunohistochemical analysis determined ATTR amyloidosis in all cases. In patients with rapidly progressive heart failure, the postmortem examination revealed multiple sites of interstitial amyloid deposits and focal cardiosclerosis in the myocardium. Pre-existing cardiac amyloidosis contributes to the aggressive clinical course of COVID-19. Coupled with the toxic effect of the SARS-CoV-2 virus on the myocardium, the disease may lead to progressive heart failure and poor outcomes.

Source link

Zarina Gioeva www.mdpi.com